Improving co-amorphous drug formulations by the addition of the highly water soluble amino acid, Proline

Pharmaceutics

Volumn 6, Issue 3, 2014, Pages 416-435

  Jensen, Katrine Tarp ^a   Löbmann, Korbinian ^a   Rades, Thomas ^a   Grohganz, Holger ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amino acid; Co amorphous; Dissolution rate; Dsc; Ftir; Salt formation; Solid state analysis; Stability; Xrpd

Indexed keywords

ARGININE; NAPROXEN; PROLINE; TRYPTOPHAN;

ARTICLE; BALL MILLING; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MIXTURE; DRUG SOLUBILITY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; INFRARED SPECTROSCOPY; MOLECULAR INTERACTION; PHYSICAL CHEMISTRY; ROOM TEMPERATURE; SOLID STATE; X RAY POWDER DIFFRACTION;

EID: 84904310486     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics6030416     Document Type: Article

References (36)

1. Amidon, G.L.; Lennernas, H.; Shah, V.P.; Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
2. Hancock, B.C.; Zografi, G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997, 86, 1-12.
3. Yu, L. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 2001, 48, 27-42.
4. Forster, A.; Hempenstall, J.; Rades, T. Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. J. Pharm. Pharmacol. 2001, 53, 303-315.
5. Van Drooge, D.J.; Hinrichs, W.L.J.; Visser, M.R.; Frijlink, H.W. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int. J. Pharm. 2006, 310, 220-229.
6. Janssens, S.; van den Mooter, G. Review: Physical chemistry of solid dispersions. J. Pharm. Pharmacol. 2009, 61, 1571-1586.
7. Serajuddin, A. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88, 1058-1066.
8. Grohganz, H.; Löbmann, K.; Priemel, P.; Tarp Jensen, K.; Graeser, K.; Strachan, C.; Rades, T. Amorphous drugs and dosage forms. J. Drug Deliv. Sci. Technol. 2013, 23, 403-408.
9. Laitinen, R.; Löbmann, K.; Strachan, C.J.; Grohganz, H.; Rades, T. Emerging trends in the stabilization of amorphous drugs. Int. J. Pharm. 2013, 453, 65-79.
10. Chieng, N.; Aaltonen, J.; Saville, D.; Rades, T. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. Eur. J. Pharm. Biopharm. 2009, 71, 47-54.
11. Allesø, M.; Chieng, N.; Rehder, S.; Rantanen, J.; Rades, T.; Aaltonen, J. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation. J. Control. Release 2009, 136, 45-53.
12. Löbmann, K.; Strachan, C.; Grohganz, H.; Rades, T.; Korhonen, O.; Laitinen, R. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur. J. Pharm. Biopharm. 2012, 81, 159-169.
13. Löbmann, K.; Grohganz, H.; Laitinen, R.; Strachan, C.; Rades, T. Amino acids as co-amorphous stabilizers for poorly water soluble drugs-Part 1: Preparation, stability and dissolution enhancement. Eur. J. Pharm. Biopharm. 2013, 85, 873-881.
14. Lobmann, K.; Laitinen, R.; Strachan, C.; Rades, T.; Grohganz, H. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs-Part 2: Molecular interactions. Eur. J. Pharm. Biopharm. 2013, 85, 882-888.
15. Mura, P.; Maestrelli, F.; Cirri, M. Ternary systems of naproxen with hydroxypropyl-β-cyclodextrin and aminoacids. Int. J. Pharm. 2003, 260, 293-302.
16. Hirano, A.; Kameda, T.; Arakawa, T.; Shiraki, K. Arginine-assisted solubilization system for drug substances: Solubility experiment and simulation. J. Phys. Chem. B 2010, 114, 13455-13462.
17. Qi, X.; Zhang, J.; Wang, W.; Cao, D. Solubility and stability of indomethacin in arginine-assisted solubilization system. Pharm. Dev. Technol. 2013, 18, 852-855.
18. Mura, P.; Bettinetti, G.P.; Cirri, M.; Maestrelli, F.; Sorrenti, M.; Catenacci, L. Solid-state characterization and dissolution properties of naproxen-arginine-hydroxypropyl-β-cyclodextrin ternary system. Eur. J. Pharm. Biopharm. 2005, 59, 99-106.
19. Serajuddin, A. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 2007, 59, 603-616.
20. Duggan, K.C.; Hermanson, D.J.; Musee, J.; Prusakiewicz, J.J.; Scheib, J.L.; Carter, B.D.; Banerjee, S.; Oates, J.A.; Marnett, L.J. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat. Chem. Biol. 2011, 7, 803-809.
21. Berlin, E.; Pallansch, M. Densities of several proteins and L-amino acids in the dry state. J. Phys. Chem. 1968, 72, 1887-1889.
22. Gordon, M.; Taylor, J.S. Ideal copolymers and the second-order transitions of synthetic rubbers. I. non-crystalline copolymers. J. Appl. Chem. 1952, 2, 493-500.
23. Yu, L.; Reutzel-Edens, S.M.; Mitchell, C.A. Crystallization and polymorphism of conformationally flexible molecules: Problems, patterns, and strategies. Org. Process Res. Dev. 2000, 4, 396-402.
24. Mura, P.; Faucci, M.T.; Bettinetti, G.P. The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-P-cyclodextrin. Eur. J. Pharm. Sci. 2001, 13, 187-194.
25. Braun, D.E.; Ardid-Candel, M.; D'Oria, E.; Karamertzanis, P.G.; Arlin, J.-B.; Florence, A.J.; Jones, AG.; Price, S.L. Racemic naproxen: A multidisciplinary structural and thermodynamic comparison with the enantiopure form. Cryst. Growth Des. 2011, 11, 5659-5669.
26. Löbmann, K.; Laitinen, R.; Grohganz, H.; Gordon, K.C.; Strachan, C.; Rades, T. Coamorphous drug systems: Enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol. Pharm. 2011, 8, 1919-1928.
27. Mattern, M.; Winter, G.; Kohnert, U.; Lee, G. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems. Pharm. Dev. Technol. 1999, 4, 199-208.
28. Izutsu, K.-I.; Fujimaki, Y.; Kuwabara, A.; Aoyagi, N. Effect of counterions on the physical properties of L-arginine in frozen solutions and freeze-dried solids. Int. J. Pharm. 2005, 301, 161-169.
29. Heinz, A.; Strachan, C.J.; Gordon, K.C; Rades, T. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J. Pharm. Pharmacol. 2009, 61, 971-988.
30. Löbmann, K.; Laitinen, R.; Grohganz, H.; Strachan, C.; Rades, T.; Gordon, K.C. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin. Int. J. Pharm. 2013, 453, 80-87.
31. Del Arco, M.; Gutiérrez, S.; Martín, C.; Rives, V.; Rocha, J. Synthesis and characterization of layered double hydroxides (LDH) intercalated with non-steroidal anti-inflammatory drugs (NSAID). J. Solid State Chem. 2004, 177, 3954-3962.
32. 1. Spectrochim. Acta Part A 2006, 64, 987-1001.
33. Cao, X.; Fischer, G. Infrared spectral, structural, and conformational studies of zwitterionic L-tryptophan. J. Phys. Chem. A 1999, 103, 9995-10003.
34. Pearson, J.F.; Slifkin, M.A. The infrared spectra of amino acids and dipeptides. Spectrochim. Acta Part A 1972, 28, 2403-2417.
35. Mary, Y.S.; Ushakumari, L.; Harikumar, B.; Varghese, H.T.; Panicker, C.Y. FT-IR, FT-raman and SERS spectra of L-proline. J. Iran. Chem. Soc. 2009, 6, 138-144.
36. Duddu, S.; dal Monte, P. Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. Pharm. Res. 1997, 14, 591-595.